Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2015

View Archived Issues

Gene delivery therapy shows promising effects on experimental autoimmune myocarditis

AstraZeneca reviews recent pipeline activities of second quarter 2015

Novel potent and selective EP4 receptor antagonist for pain-management

Orkambi benefits patients with cystic fibrosis in phase III studies; product launch underway

The J. David Gladstone Institutes divulge autophagy inducers

Lilly designs FFAR1 agonists

Mitsubishi Tanabe Pharma presents milestones of first quarter of fiscal 2015

CSL completes acquisition of Novartis influenza vaccine business

First 3D printed drug product approved by FDA

FDA grants orphan drug designation to veltuzumab for ITP

The European Comission grants orphan drug designation to Soligenix's SGX-301

Exalenz Bioscience's BreathID to be tested in GR-MD-02 trial

Teva to buy controlling interest in analytics company Immuneering

Euclises Pharmaceuticals patents COX-2 inhibitors/NO-releasing prodrugs

Columbia University in the City of New York discloses SLC7A11 inhibitors

3-V Biosciences describes fatty acid synthase inhibitors

Merck Patent synthesizes IRAK inhibitors

Celgene exercises option to license GI-6207

Progenics forms agreement with Johns Hopkins University for prostate cancer imaging agent

CureVac and Gates Foundation to collaborate on RSV vaccine development

Minerva Biotechnologies licenses iPSC IP from iPS Academia Japan

MedImmune and Mirati to conduct trial combining durvalumab and mocetinostat

Anavex Life Sciences discloses preliminary phase IIa results for Anavex 2-73

Pharmaxis and Synairgen form collaboration to target LOXL2 for IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...